We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

QIAGEN and GENEART Partner to Commercialize Synthetic Human Genes

News   May 15, 2008

 
QIAGEN and GENEART Partner to Commercialize Synthetic Human Genes
 
 
 

RELATED ARTICLES

$3.6 Million to Study Adverse Effects of Genome Editing

News

As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.

READ MORE

Promising Marker for Immune Invasion and Immunotherapy Failure

News

An extracellular matrix gene signature has been identified which is associated with response to immunotherapy, and provides a hypothesis about why some people don't respond.

READ MORE

Dermal Fibroblasts Gain Adipogenic Traits with Age

News

A study in mice showed that cells lose their identity and acquire adipogenic traits, as a mechanism underlying cellular aging.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE